Cancer stem cells: perspectives for therapeutic targeting

Cristina Maccalli, Ruggero De Maria

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Cells with “stemness” and tumor-initiating properties have been isolated from both hematological and solid tumors. These cells denominated as cancer stem cells (CSCs), representing rare populations within tumors, have the ability to metastasize and are resistant to standard therapies and immunotherapy. Heterogeneity and plasticity in the phenotype of CSCs have been described in relation to their tissue origin. Few definitive markers have been isolated for CSCs from human solid tumors, limiting their usage for in vivo identification of these cells. Nevertheless, progress in the emerging CSCs concept has been achieved gaining, at least for some type of tumors, their biological and immunological characterization. The recent identification of molecules and signaling pathways that are up-regulated or aberrantly induced in CSCs allowed the development of small agents for specifically targeting of CSCs. A general low immunogenic profile has been reported for CSCs with, in some cases, the identification of the mechanisms responsible of the impairment of cell-mediated immune responses. These concepts are discussed in the context of this review. Although CSCs still need to be fully characterized, potential candidate markers and/or signaling pathways, to be exploited for the design of novel CSC-targeting therapeutic strategies, are described in this review.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalCancer Immunology, Immunotherapy
Volume64
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Therapeutics
Neoplasms
Immunotherapy
Phenotype

Keywords

  • Cancer stem cells
  • Cancer stem cells-associated signaling pathways
  • CSC-targeted therapies
  • Immune modulation
  • Immunological profile
  • NIBIT 2013

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Cancer stem cells : perspectives for therapeutic targeting. / Maccalli, Cristina; De Maria, Ruggero.

In: Cancer Immunology, Immunotherapy, Vol. 64, No. 1, 01.01.2015, p. 91-97.

Research output: Contribution to journalReview article

@article{39df104368034d5e9a90e512ba8176a4,
title = "Cancer stem cells: perspectives for therapeutic targeting",
abstract = "Cells with “stemness” and tumor-initiating properties have been isolated from both hematological and solid tumors. These cells denominated as cancer stem cells (CSCs), representing rare populations within tumors, have the ability to metastasize and are resistant to standard therapies and immunotherapy. Heterogeneity and plasticity in the phenotype of CSCs have been described in relation to their tissue origin. Few definitive markers have been isolated for CSCs from human solid tumors, limiting their usage for in vivo identification of these cells. Nevertheless, progress in the emerging CSCs concept has been achieved gaining, at least for some type of tumors, their biological and immunological characterization. The recent identification of molecules and signaling pathways that are up-regulated or aberrantly induced in CSCs allowed the development of small agents for specifically targeting of CSCs. A general low immunogenic profile has been reported for CSCs with, in some cases, the identification of the mechanisms responsible of the impairment of cell-mediated immune responses. These concepts are discussed in the context of this review. Although CSCs still need to be fully characterized, potential candidate markers and/or signaling pathways, to be exploited for the design of novel CSC-targeting therapeutic strategies, are described in this review.",
keywords = "Cancer stem cells, Cancer stem cells-associated signaling pathways, CSC-targeted therapies, Immune modulation, Immunological profile, NIBIT 2013",
author = "Cristina Maccalli and {De Maria}, Ruggero",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1592-1",
language = "English",
volume = "64",
pages = "91--97",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Cancer stem cells

T2 - perspectives for therapeutic targeting

AU - Maccalli, Cristina

AU - De Maria, Ruggero

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cells with “stemness” and tumor-initiating properties have been isolated from both hematological and solid tumors. These cells denominated as cancer stem cells (CSCs), representing rare populations within tumors, have the ability to metastasize and are resistant to standard therapies and immunotherapy. Heterogeneity and plasticity in the phenotype of CSCs have been described in relation to their tissue origin. Few definitive markers have been isolated for CSCs from human solid tumors, limiting their usage for in vivo identification of these cells. Nevertheless, progress in the emerging CSCs concept has been achieved gaining, at least for some type of tumors, their biological and immunological characterization. The recent identification of molecules and signaling pathways that are up-regulated or aberrantly induced in CSCs allowed the development of small agents for specifically targeting of CSCs. A general low immunogenic profile has been reported for CSCs with, in some cases, the identification of the mechanisms responsible of the impairment of cell-mediated immune responses. These concepts are discussed in the context of this review. Although CSCs still need to be fully characterized, potential candidate markers and/or signaling pathways, to be exploited for the design of novel CSC-targeting therapeutic strategies, are described in this review.

AB - Cells with “stemness” and tumor-initiating properties have been isolated from both hematological and solid tumors. These cells denominated as cancer stem cells (CSCs), representing rare populations within tumors, have the ability to metastasize and are resistant to standard therapies and immunotherapy. Heterogeneity and plasticity in the phenotype of CSCs have been described in relation to their tissue origin. Few definitive markers have been isolated for CSCs from human solid tumors, limiting their usage for in vivo identification of these cells. Nevertheless, progress in the emerging CSCs concept has been achieved gaining, at least for some type of tumors, their biological and immunological characterization. The recent identification of molecules and signaling pathways that are up-regulated or aberrantly induced in CSCs allowed the development of small agents for specifically targeting of CSCs. A general low immunogenic profile has been reported for CSCs with, in some cases, the identification of the mechanisms responsible of the impairment of cell-mediated immune responses. These concepts are discussed in the context of this review. Although CSCs still need to be fully characterized, potential candidate markers and/or signaling pathways, to be exploited for the design of novel CSC-targeting therapeutic strategies, are described in this review.

KW - Cancer stem cells

KW - Cancer stem cells-associated signaling pathways

KW - CSC-targeted therapies

KW - Immune modulation

KW - Immunological profile

KW - NIBIT 2013

UR - http://www.scopus.com/inward/record.url?scp=84925031798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925031798&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1592-1

DO - 10.1007/s00262-014-1592-1

M3 - Review article

C2 - 25104304

AN - SCOPUS:84925031798

VL - 64

SP - 91

EP - 97

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -